---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-006038"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2024-09-30T23:59:59+00:00"
generated_at: "2026-05-31T01:02:53.948334+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# VolitionRx appoints Dr. Ethel Rubin as independent director; board expands to 7

## Summary
- Dr. Rubin appointed effective Sept 30, 2024; board increased from 6 to 7 members.
- She will serve on both the Audit Committee and the Compensation Committee.
- Compensation: $10,840 per quarter plus 15,000 RSUs vesting over 3 years.
- Dr. Rubin brings 20+ years life sciences experience; previously at Medtronic and BioHealth Innovation.
- She contributed to over 25 commercial products and multiple M&A, partnerships.

## SEC filing metadata
- accession: 0001477932-24-006038
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2024-09-30T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793224006038/0001477932-24-006038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793224006038/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-006038
- JSON: https://secwatch.observer/filing/0001477932-24-006038.json
- Plain text: https://secwatch.observer/filing/0001477932-24-006038.txt

## Key facts
- Executive change
  Dr. Ethel Rubin was appointed as Director at VOLITIONRX LTD.
  - Action: appointed
  - Role: Director
  source text: On September 30, 2024, the Board of Directors (the “ Board ”) of VolitionRx Limited (the “ Company ”), pursuant to the Company’s Bylaws, passed a resolution to increase the size of the Board to seven (7) members and appointed Dr. Ethel Rubin to fill the new vacancy on the Board effective as of September 30, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/93314/000147793224006038/0001477932-24-006038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.